Close Menu

financial results

OpGen expects to begin clinical validation studies for the AMR Gene Panel u5.47 for complicated urinary tract infections in Q4.

Veracyte attributed its lower Afirma sales in part to slowing down the rollout of an updated version of the test that relies on RNA sequencing.

Fulgent missed the consensus Wall Street estimates on the top and bottom lines. Its CEO said the firm continues to invest in technology and in streamlining its operations.

The genomic testing company's total revenues were down to $17.5 million in the quarter, although its genomic testing volume increased 14 percent.

Qiagen reported third quarter revenues of $364.0 million, up from $338.7 million a year ago and just above analysts' average estimate of $363.3 million.

The genetic testing firm posted revenues of $18.1 million for the quarter, compared with $6.3 million for the year-ago period.

The revenue increase was driven by higher test volumes in its reproductive health segment and improved test reimbursement across all segments.

The company reported signed agreements for 295 instruments, while revenue-generating placements have grown to 56. 

Third quarter sales of $535.0 million beat analysts' average estimate of $508 million and represented 3 percent growth on a currency-neutral basis.

GenMark placed 65 ePlex analyzers in Q3, the first full quarter after the platform's launch in the US, and it expects to exit 2017 with up to 200 placements.